BCR and chronic myelogenous leukemia, BCR-ABL1 positive: To study the mechanism resulting in impaired CML cell biology upon TNFα inhibition we applied 32D Bcr-Abl cells that were subjected to TNFα antibody treatment, nilotinib therapy or the combination, upon adding or not adding physiological TNFα concentration.